| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 08/01/2002 | WO2001097862A3 Stabiliser for radiopharmaceuticals |
| 08/01/2002 | WO2001089538A3 Apoptotic entities for use in treatment of endothelium dysfunction disorders |
| 08/01/2002 | WO2001089319A3 Tryptophan source from plants and uses therefor |
| 08/01/2002 | WO2001083554A3 Anti-inflammatory compounds and uses thereof |
| 08/01/2002 | WO2001083527A3 Glucagon antagonists |
| 08/01/2002 | WO2001081325A3 Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising alkyl and aryl alanine p2 moieties |
| 08/01/2002 | WO2001080633A3 Surfactant protein d for the prevention and diagnosis of pulmonary emphysema |
| 08/01/2002 | WO2001078654A3 Halogentated 2-amino-3, 4 heptenoic acid derivatives useful as nitric oxide synthase inhibitors |
| 08/01/2002 | WO2001072836A3 G-protein coupled receptors |
| 08/01/2002 | WO2001070955A3 Identification of essential genes in prokaryotes |
| 08/01/2002 | WO2001070738A3 Tri-aryl-substituted-ethane pde4 inhibitors |
| 08/01/2002 | WO2001028494A9 Nordihydroguaiaretic derivatives for use in treatment of tumors |
| 08/01/2002 | WO2001026678A9 Short segments of dap-kinase |
| 08/01/2002 | WO2000077040A9 Human intracellular signaling molecules |
| 08/01/2002 | US20020103398 Double bond acts as a rigidifying element, for unexpected potency and selectivity for inhibition of inducible nitric oxide synthase over the constitutive isoforms |
| 08/01/2002 | US20020103389 Klainetins and their derivatives, method for their preparation and use thereof |
| 08/01/2002 | US20020103380 Thiourea and urea liquid-phase combinatorial libraries: synthesis and apoptosis induction |
| 08/01/2002 | US20020103371 Substituted imidazo [1,5-a] [1,2,4] triazolo [4,3-d] [1,4] benzodiazepine derivatives |
| 08/01/2002 | US20020103345 Bispecific immunoglobulin-like antigen binding proteins and method of production |
| 08/01/2002 | US20020103340 Rab proteins |
| 08/01/2002 | US20020103334 Aprotinin variants having a net charge of +3 to -3 at pH 7 and with the amino acids Arg15 or Arg15-Ala17 in the binding region; serine protease inhibitor |
| 08/01/2002 | US20020103260 Combinations of formoterol and fluticasone proppionate for asthma |
| 08/01/2002 | US20020103249 Combination of a serotonin reuptake inhibitor and irindalone |
| 08/01/2002 | US20020103248 Indole derivatives which are agonists of the progesterone receptor and useful for treatment of carcinoma and adenocarcinomas of uterine leiomyomata, endometriosis or polycystic ovary syndorme in a mammal |
| 08/01/2002 | US20020103247 Indole and dihydroindole derivatives |
| 08/01/2002 | US20020103245 1-aryl or heteroaryl substituted 5-amino-4 carbonylpyrazole derivatives; antiinflammatory agents |
| 08/01/2002 | US20020103244 Antifatigue composition |
| 08/01/2002 | US20020103239 Such as N-hydroxy-2-(((4-phenoxyphenyl)-sulfonyl)methyl) benzamide which inhibits matrix metalloprotease activity |
| 08/01/2002 | US20020103234 Heterocycl-containing carboxylic acid derivative and drug containing the same |
| 08/01/2002 | US20020103230 Heterocyclic compounds |
| 08/01/2002 | US20020103227 Nitric oxide synthase inhibitors such as 6(4'-(4-phenethyl-piperazin-1-ylmethyl)-biphenyl-4-yl)-pyridin-2-ylamine for treatment and prevention of central nervous system disorders |
| 08/01/2002 | US20020103225 Comprises solid amorphous dispersion of compounds such as (2R,4S)4-((3,5-dichloro-benzyl)-methoxycarbonyl-amino)-6,7-dimethoxy-2 -methyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester for elevating plasma lipid levels |
| 08/01/2002 | US20020103221 Such as 2-amino-N-(2-(3a-(R)-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydro-pyrazolo -(4,3-c)pyridin-5-yl)-1-(R)-benzyloxymethyl- 2-oxo-ethyl)-isobutyramide or prodrug thereof; for improving functional health of elderly/isolated |
| 08/01/2002 | US20020103213 Pyrimidone compounds which are inhibitors of the enzyme Lp-PLA2; use in treating atheroscelerosis |
| 08/01/2002 | US20020103211 For treatment of chronic inflammatory disease, chronic intestinalinflammation, arthritis, psoriasis, asthma, autoimmune disorders |
| 08/01/2002 | US20020103203 For treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, psoriasis |
| 08/01/2002 | US20020103202 Heteroaryl-phenyl substituted factor Xa inhibitors |
| 08/01/2002 | US20020103198 Acylamino cyclopropane derivatives |
| 08/01/2002 | US20020103186 Use against multiply resistant gram positive pathogens; have a diazine moiety attached to the phenyloxazolidinone which is further substituted by heterocyclic, aryl, substituted aryl, heteroaroamatic ring |
| 08/01/2002 | US20020103184 Cyclic malonamides as inhibitors of a beta protein production |
| 08/01/2002 | US20020103180 Methods, compositions and articles for reducing or preventing the effects of inflammation |
| 08/01/2002 | US20020103178 Administering steriods (e.g. estrogens), wherein a non-fused polycyclic, hydrophobic substituent such as adamantanyl is attached to the hydroxy-substituted A-ring thereof |
| 08/01/2002 | US20020103167 Method of treating certain eye diseases |
| 08/01/2002 | US20020103166 2-(4-Chlorophenoxy)-2-oxo-1,3,2-oxazaphosphorinane-3-aceto -hydroxamic acid, for example; antiathritic, -tumor, -metastasis, -proliferative and -ulcer agents; multiple sclerosis; vision defects; skin disorders |
| 08/01/2002 | US20020103162 Use of threo-methylphenidate compounds to enhance memory |
| 08/01/2002 | US20020103148 Vectors comprising SAR elements |
| 08/01/2002 | US20020103141 DNA topoisomerase I and cyclooxygenase-2 (COX-2) inhibiting agents |
| 08/01/2002 | US20020103123 Administering coumpounds such as aromatic alkyl diamine derivatives as Y5 receptor agonist or antagonist to increase or decrease food consumption |
| 08/01/2002 | US20020103121 Amino acid sequence of residues 163-199 used to induce apoptosis in a cell |
| 08/01/2002 | US20020103115 Useful in the development of human therapeutics and diagnostic compositions and methods |
| 08/01/2002 | US20020103111 Comprising peptide sequences which mimic the conserved amino acid motif LDTSL of MAdCAM-1 and which have groups bonded to the N- and C- termini; treatment of inflammatory bowel disease |
| 08/01/2002 | US20020102726 Which forms a reconstructed epidermis, used to test various factors on human skin equivalent, such as drugs, cosmetics, surfactants and detergents |
| 08/01/2002 | US20020102710 Polypeptide for use in the treatment of cancer, autoimmune diseases and inflammation |
| 08/01/2002 | US20020102658 Human monoclonal antibody against a costimulatory signal transduction molecule AILIM and pharmaceutical use thereof |
| 08/01/2002 | US20020102649 Human transport protein homologs |
| 08/01/2002 | US20020102643 Dorsal tissue affecting factor and compositions |
| 08/01/2002 | US20020102642 Nuclelotide sequences coding preferential protein for use in therapeutic, diagnostic and medical imaging |
| 08/01/2002 | US20020102609 Antagonists of HMG1 for treating inflammatory conditions |
| 08/01/2002 | US20020102552 Nucleotide sequences coding preferential polypeptide for use in the treatment of diabetes and eating disorders |
| 08/01/2002 | US20020102535 Nucleic acid molecules and polypeptides for immune modulation |
| 08/01/2002 | US20020102317 For accelerating and amplifying the synthesis of thermal shock proteins of cells of living beings |
| 08/01/2002 | US20020102265 For diagnosis and imaging of cancer and tumor tissues |
| 08/01/2002 | US20020102249 Administering to an individual in need of treatment thereof an effective amount of dermatan sulfate or chondroitin sulfate degrading enzyme to modulate fibrous tissue formation |
| 08/01/2002 | US20020102235 Novel imidazolidinones as NS3-serine protease inhibitors of hepatitis C virus |
| 08/01/2002 | US20020100854 Furnace mount and method of installation |
| 08/01/2002 | DE10103647A1 Verfahren zur Herstellung eines Pyrazolo (4,3-d) pyrimidinderivates A process for preparing a pyrazolo (4,3-d) pyrimidine derivative |
| 08/01/2002 | DE10102977A1 Testsystem zur Entwicklung von Therapeutika, insbesondere von Wirkstoffen zur Behandlung von Osteoporose Test system for the development of therapeutics, in particular of drugs used to treat osteoporosis |
| 08/01/2002 | DE10100911A1 Verfahren zur Hormonersatztherapie und dessen Darreichungsform A method for hormone replacement therapy and its dosage form |
| 08/01/2002 | CA2735478A1 Malonyl-coa decarboxylase inhibitors useful as metabolic modulators |
| 08/01/2002 | CA2735267A1 Malonyl-coa decarboxylase inhibitors useful as metabolic modulators |
| 08/01/2002 | CA2436139A1 Methods of inducing organ transplant tolerance and correcting hemoglobinopathies |
| 08/01/2002 | CA2435884A1 Process for the preparation of a pyrazolo[4,3-d]pyrimidine derivative |
| 08/01/2002 | CA2435883A1 Benzylamine analogue |
| 08/01/2002 | CA2435829A1 Trisubstituted carbocyclic cyclophilin binding compounds and their use |
| 08/01/2002 | CA2435801A1 Styrene derivative and process for preparing the same |
| 08/01/2002 | CA2435775A1 2h-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof |
| 08/01/2002 | CA2435653A1 Anti-cancer 2,3-dihydro-1h-pyrrolo[3,2-f]quinoline complexes of cobalt and chromium |
| 08/01/2002 | CA2435566A1 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands |
| 08/01/2002 | CA2435510A1 Methods for screening for substances which inhibit fp prostanoid receptor interaction with a compound having pgf2.alpha.alphaactivity and methods of treating cancer |
| 08/01/2002 | CA2435409A1 Novel cannabimimetic ligands |
| 08/01/2002 | CA2435143A1 Halogen compounds having thrombopoietin receptor agonism |
| 08/01/2002 | CA2435124A1 Formulation of boronic acid compounds |
| 08/01/2002 | CA2435097A1 Peptides exibiting affinity for the viral protein gp120, and use of the se peptides |
| 08/01/2002 | CA2435047A1 Constitutively desensitized g protein-coupled receptors |
| 08/01/2002 | CA2434584A1 Pharmaceutical compositions, dosage forms and methods for oral administration of epothilones |
| 08/01/2002 | CA2434504A1 Combinations of sterol absorption inhibitor(s) with blood modifiers for treating vascular conditions |
| 08/01/2002 | CA2434488A1 Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications |
| 08/01/2002 | CA2434436A1 Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions |
| 08/01/2002 | CA2434430A1 The use of substituted azetidinone compounds for the treatment of sitosterolemia |
| 08/01/2002 | CA2434320A1 Chemokines as adjuvants of immune response |
| 08/01/2002 | CA2434085A1 Cyclin dependent kinase inhibiting purine derivatives |
| 08/01/2002 | CA2434033A1 Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
| 08/01/2002 | CA2433530A1 New film coating |
| 08/01/2002 | CA2432985A1 Piperazine- and piperidine-derivatives as melanocortin receptor agonists |
| 08/01/2002 | CA2432276A1 Regulation of cell growth by muc1 |
| 08/01/2002 | CA2432122A1 Aryl and aminoaryl substituted serotonin receptor agonist and antagonist ligands |
| 08/01/2002 | CA2431996A1 Melanocortin receptor agonists |
| 08/01/2002 | CA2431970A1 Substituted pyrazinoquinoxaline derivatives as serotonin receptor agonists and antagonists |
| 08/01/2002 | CA2431493A1 Aminoacyl trna synthetases |
| 08/01/2002 | CA2431177A1 Trem-1 splice variant for use in modifying immune responses |